Generic and Non-Prescription Drugs Sector Outlook — September 2026
A sector view of Generic and Non-Prescription Drugs, covering how public markets price complex generics, branded off-patent portfolios and consumer self-care brands, with precedent transaction benchmarks. Built for owners, boards and acquirers assessing where a business sits in this range.
For information only. Not an appraisal or a fairness opinion.
What moved since: Generic and Non-Prescription Drugs M&A update, 14–28 September 2026
Key figures
- Sector median EV/EBITDA
- 7.5x
- CY2027E, 7 of 10 companies rated
- Top-tier multiple
- 12.3x
- 2 names at top of range
- Complex generics share of set
- 70%
- 7 of 10 companies
- Consumer self-care deal multiple
- 13.6x
- Haleon plc, disclosed terms
Read the report
1 / 21 · HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › GENERIC AND NON-PRESCRIPTION DRUGS
Executive summary
Generic and Non-Prescription Drugs is priced in three tiers rather than as one market. Across the 7 of 10 companies with a forward EV/EBITDA estimate for CY2027E, the sector median sits at 7.5x, with two names at the top of the range at 12.3x and one name at the bottom at 6.9x. The higher multiples sit with faster-growing names that carry thinner margins, and consumer self-care assets draw the highest disclosed multiples among the precedent transactions shown.
Key findings
- Complex generics account for 7 of 10 names in this peer set.
- This sector prices in three tiers, not as one market.
- Faster-growing names trade at higher multiples but thinner margins.
- Consumer self-care assets draw the highest disclosed deal multiples.
What each page shows
The analyst’s walkthrough of the deck, page by page.
- 01
HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › GENERIC AND NON-PRESCRIPTION DRUGS
This is the cover page for the Generic and Non-Prescription Drugs sector report, dated September 28, 2026.
We open this sector view of Generic and Non-Prescription Drugs, capturing where the market stands as of September 28, 2026. Over the pages that follow, we show how this market prices three distinct groups of businesses, so what a reader takes away is where value concentrates in this set.
Everything on this page
HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › GENERIC AND NON-PRESCRIPTION DRUGS Generic and Non-Prescription Drugs: Three Price Tiers How the market is pricing complex generics, branded off-patent portfolios and consumer self-care across this peer set, and what separates the top of the range from the bottom. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / EBITDA (CY2027E) Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1
- 02CONTENTS
What This Report Covers
This page lists the report's five sections plus an appendix, in order.
We lay out the five sections ahead — the bottom line, the landscape, valuation and situations, precedent transactions, and strategic implications — plus a full appendix. We put the bottom line first, so a reader who only has time for one section still gets the complete argument.
Everything on this page
CONTENTS What This Report Covers 01 The Bottom Line The Structure Behind the Price in Generic and Non-Prescription Drugs 02 The Landscape Complex Generics Account for Seven of the Ten Names on This Page 03 Valuation & Situations Two Names Hold the Top of This Range, and One Sits at the Bottom 04 Precedent Transactions Consumer Self-Care Assets Draw the Higher Disclosed Multiples 05 Strategic Implications What This Range Rewards, and What Sits at the Bottom of It 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2
- 0301 · THE BOTTOM LINE
Generic and Non-Prescription Drugs Is Priced in Three Tiers, and Complex Generics Hold Most of the Set
This page states the report's central finding: the sector prices in three tiers, with complex generics holding most of the set.
We find that Generic and Non-Prescription Drugs prices in three tiers rather than as a single market. Across the 7 of 10 companies carrying a forward EV/EBITDA estimate for CY2027E, the median sits at 7.5x, two names at the top of the range sit at 12.3x, and the one name at the bottom sits at 6.9x. Complex generics manufacturers make up 70% of this set, so the pricing conversation here runs mostly through filing and manufacturing capability. That's the one page we'd leave with if we only had a minute.
Everything on this page
01 · THE BOTTOM LINE Generic and Non-Prescription Drugs Is Priced in Three Tiers, and Complex Generics Hold Most of the Set The full story on one page · figures on EV / EBITDA (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / EBITDA on CY2027E consensus (7 of 10 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Qualitative characterisations are NeuraCap views. Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 The Two Ends of This Set Are Priced on Different Terms Across the 7 of the 10 companies with a forward estimate, the middle of the range sits at 7.5x forward EV / EBITDA for CY2027E. The 2 names at the top of the range sit at 12.3x, and the single name at the bottom sits at 6.9x. 2 The Higher Prices Sit with the Faster Growers Split at 5% forward growth, the 4 faster-growing names of the 7 with a forward estimate sit at 9.0x, against 7.4x for the other 3. Both names at the top of the range run EBITDA margins below the covered middle, so buyers are accepting thinner margins alongside faster forward growth. 3 Complex Generics Are the Centre of Gravity Here Specialty and complex generics manufacturers are 7 of the 10 companies on this page, 70% of the set, and 6 of them carry a forward estimate. Branded off-patent and prescription portfolios are 2 names at 20%, and consumer self-care brands are a single name at 10%, so the pricing conversation runs from plant and filings capability to shelf position. 4 Consumer Self-Care Brands Draw the Higher Deal Multiples Across the 9 transactions shown here, consumer self-care assets carry the higher disclosed EV / EBITDA marks, with Haleon plc recorded at 13.6x. The Opella Healthcare SAS (Sanofi Consumer Health Business) carve-out to Clayton, Dubilier & Rice LLC was recorded at 8.8x, which is where that sponsor separation from a prescription parent was agreed. 7.5x Sector median EV/EBITDA CY2027E consensus · 7 rated of 10 companies 12.3x Premium end EV/EBITDA vs 6.9x at the discount end top quartile (n=2) against bottom quartile (n=1) on EV/EBITDA — the spread the report explains 25 Transactions with disclosed terms 54 recorded in this tier · 1 told as case studies, the full list in the appendix
- 04SECTION 02
02
This divider introduces Section 02, the market map of the sector's three groups.
We move now into the landscape: three groups sit under one sector label, each with its own scale, growth and margin profile. Here's who sits in each group and what buyers examine in each one.
Everything on this page
SECTION 02 02 THE LANDSCAPE Complex Generics Account for Seven of the Ten Names on This Page Three groups, who sits in each, and what buyers examine in each. 02 of 06 Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4
- 0502 · MARKET MAP
One Sector Label Covers Three Groups with Different Scale, Growth and Margin Profiles
This page groups the 10 approved companies into three business segments and shows the median valuation for each.
We group the ten companies in this set into three segments — complex generics, branded off-patent portfolios, and consumer self-care brands. Each group carries its own median EV/EBITDA on a CY2027E basis, and its own scale and margin profile. Complex generics carries the largest share of names, so it sets the tone for how this sector gets discussed. That's why we treat segment first, before we get to any single company.
Everything on this page
02 · MARKET MAP One Sector Label Covers Three Groups with Different Scale, Growth and Margin Profiles 10 approved companies grouped by business segment · median EV / EBITDA (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 SPECIALTY AND COMPLEX GENERICS MANUFACTURERS 7 cos median 9.0x Teva (TEVA) Viatris (VTRS) Dr. Reddy's (RDY) Amneal (AMRX) Perrigo Company (PRGO) Regencell (RGC) Amphastar (AMPH) The manufacturing and filings engine of the sector: dosage-form capability, sterile injectable capacity and launch cadence are what buyers examine first. BRANDED OFF-PATENT AND PRESCRIPTION GENERIC PORTFOLIOS 2 cos 6.9x · 1 rated Liquidia (LQDA) Prestige (PBH) Recurring earnings on established molecules, where durability against base business erosion and loss of exclusivity is the live question. CONSUMER SELF-CARE AND PERSONAL CARE BRAND PORTFOLIOS 1 cos no rated names Kenvue (KVUE) Shelf position, monograph protection and Rx-to-OTC switch optionality, priced closer to consumer staples than to filings and plants.
- 0602 · LANDSCAPE
Complex Generics Carry Most of the Names, and Most of the Estimates
This page shows that complex generics carries most of the names and most of the covered valuation estimates in this set.
We show here that complex generics manufacturers hold most of the names in this universe, and most of the forward estimates the market has published. The other two groups — branded off-patent portfolios and consumer self-care — are smaller in count but still shape the range. Full company-level detail sits in the appendix for a reader who wants to check any single name. So the read here is concentration, not diversity.
Everything on this page
02 · LANDSCAPE Complex Generics Carry Most of the Names, and Most of the Estimates Segment view of the approved universe · EV / EBITDA (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/EBITDA Names to know What they do — and why it matters Specialty and complex generics manufacturers 7 70% 9.0x Teva Pharmaceutical Industries Limited (TEVA) · Viatris Inc. (VTRS) · +5 more Seven names, the sector core. ANDA portfolios, sterile injectable and fill-finish capacity and complex dosage forms sit in this group, which is 70% of the set here. Six of the seven carry a forward estimate, so this group shapes most of what the valuation page shows. Branded off-patent and prescription generic portfolios 2 20% 6.9x n=1 Liquidia Corporation (LQDA) · Prestige Consumer Healthcare Inc. (PBH) Two names, recurring earnings. Branded off-patent and prescription portfolios are 20% of the set, and one of the two carries a forward estimate, so read this group's pricing as a single name rather than a band. Diligence here turns on how durable the earnings base looks as additional filers arrive. Consumer self-care and personal care brand portfolios 1 10% — Kenvue Inc. (KVUE) One name, consumer staples logic. A single name, 10% of the set, without a forward EBITDA estimate in this data. The transaction record is where this group's pricing shows up, and it is where the disclosed EBITDA marks on this page are concentrated.
- 07SECTION 03
03
This divider introduces Section 03, on public market valuation across the rated names.
We turn next to valuation: two names hold the top of this range, and one sits at the bottom. All ten companies appear here, though only seven carry a forward EV/EBITDA estimate for CY2027E.
Everything on this page
SECTION 03 03 VALUATION & SITUATIONS Two Names Hold the Top of This Range, and One Sits at the Bottom All 10 companies appear; 7 carry a forward EV / EBITDA estimate for CY2027E. 03 of 06 Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7
- 0803 · PUBLIC MARKET VALUATION
Two Names Hold the Top of This Range, and They Are the Faster Growers
This page ranks the seven rated companies by EV/EBITDA (CY2027E) and shows where the sector median falls.
We rank the seven rated companies on EV/EBITDA for CY2027E, sorted from the highest multiple down. The sector median sits at 7.5x, and the two names at the top of this range are also the faster growers in the set. That pairing — higher multiple, faster growth — is the pattern we come back to through the rest of this section. So what a reader should watch is whether that growth premium holds as estimates roll forward.
Everything on this page
03 · PUBLIC MARKET VALUATION Two Names Hold the Top of This Range, and They Are the Faster Growers EV / EBITDA (CY2027E) · all 7 rated companies, sorted descending · sector median 7.5x · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / EBITDA on CY2027E consensus (7 of 10 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / EBITDA (CY2027E) basis. Panel commentary is a NeuraCap view. Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 12.3x CORE · median 7.5x DISCOUNT · median 6.9x Sector median 7.5x WHAT SEPARATES THE TWO ENDS The top end sits at 12.3x. The 2 names at the top of the range sit at 12.3x forward EV / EBITDA for CY2027E, against 6.9x for the single name at the bottom of the range. A forward multiple already credits the growth in the estimates, so a premium that survives it points to durability rather than a one-year launch effect. Growth sits at the top end. Dr. Reddy's Laboratories Limited (RDY) carries 16% forward growth and Amneal Pharmaceuticals, Inc. (AMRX) 9%, and both run EBITDA margins below the covered middle at 22% and 24%. The pairing is association rather than proof, but buyers at this end are accepting thinner margins alongside faster forward growth. Margin alone did not price it. Prestige Consumer Healthcare Inc. (PBH) runs a 33% EBITDA margin with 12% forward growth and still sits at the bottom of this range, on a base of one name. Its earnings come from branded off-patent and prescription portfolios, where the market is weighing how long that base holds.
- 0903 · VALUATION DRIVERS
Profitability Separates the Two Ends: Names Above the 26% Margin Line Carry 7.5x Against 10.6x Below It
This page splits the rated names by revenue growth and by EBITDA margin and compares the median multiple in each cohort.
We split the rated names into cohorts, once by revenue growth and once by EBITDA margin, each cut at its own covered median. Names above the 26% margin line carry a median 7.5x, against 10.6x for names below it. Growth and margin move in different directions here, so a single valuation story doesn't fit every name in this set. That's an association we observe in the data, not a claim about what causes it.
Everything on this page
03 · VALUATION DRIVERS Profitability Separates the Two Ends: Names Above the 26% Margin Line Carry 7.5x Against 10.6x Below It Median EV / EBITDA (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=4; slower n=3; higher-margin n=4; lower-margin n=3). Driver readings are NeuraCap views on the supplied data — association, not causation. Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 EV/EBITDA, median per cohort · growth split at 5% · EBITDA-margin split at 26% The Faster-Growing Group Sits at 9.0x, the Slower Group at 7.4x Split at 5% forward growth, the 4 faster-growing names of the 7 with a forward estimate carry a median of 9.0x, against 7.4x for the other 3. On a CY2027E lens the forecast is already inside the price, so the gap is about how durable that growth is judged to be. Margin on Its Own Does Not Separate the Middle of the Set Viatris Inc. (VTRS) runs a 30% EBITDA margin and Perrigo Company plc (PRGO) 18%, and both sit in the Core tier. Profitability matters to the earnings buyers underwrite, but within this set it is not what marks out the top of the range. Dosage-Form Complexity and Inspection Record Are Diligence Gates Buyers in this sector examine sterile injectable and fill-finish capability, first-to-file and exclusivity timing, and site inspection history before price is settled. This data does not measure those inputs; the deal conventions here put them early in the process, and quality findings can change what a plant contributes. Buying Consortia Sit Between the Plant and the Pharmacy Shelf Award economics in the prescription channel are negotiated with a small number of purchasing groups, and gross-to-net deductions and shelf-stock adjustments are where quality-of-earnings work concentrates. Customer concentration is therefore part of the earnings quality any multiple is applied to.
- 1003 · SITUATION MAP
The Names at the Top of the Price Range Carry Margins Below the Middle of the Set
This page maps each rated company by valuation versus the sector median and by margin versus the covered median.
We cut this page two ways: EV/EBITDA against the sector median of 7.5x, and EBITDA margin against the covered median of 26%. The names at the top of the price range sit below the middle of the set on margin, so premium pricing here doesn't track directly with profitability. These are observations on where each company sits, not recommendations. So what matters is knowing which quadrant a given name occupies before comparing it to peers.
Everything on this page
03 · SITUATION MAP The Names at the Top of the Price Range Carry Margins Below the Middle of the Set Cut on EV / EBITDA vs the sector median (7.5x) (rows) and EBITDA margin vs the covered median (26%) (columns) · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Priced up, Margin Behind It Above-median multiple · above-median EBITDA margin 2 names Teva Pharmaceutical Industries Limited (TEVA) · Amphastar Pharmaceuticals, Inc. (AMPH) Teva Pharmaceutical Industries Limited (TEVA) and Amphastar Pharmaceuticals, Inc. (AMPH) sit above the 7.5x middle of the set on forward EV / EBITDA and above the 26% covered middle on EBITDA margin. Both are specialty and complex generics manufacturers, where injectable and complex dosage-form mix is what buyers examine first. Priced up on Forward Growth Above-median multiple · below-median EBITDA margin 2 names Dr. Reddy's Laboratories Limited (RDY) · Amneal Pharmaceuticals, Inc. (AMRX) Dr. Reddy's Laboratories Limited (RDY) and Amneal Pharmaceuticals, Inc. (AMRX) hold the top of the price range with EBITDA margins below the covered middle. Their forward estimates carry growth above the split used on the drivers page, and the market is pricing that ahead of current profitability. Margin Without the Multiple Below-median multiple · above-median EBITDA margin 2 names Viatris Inc. (VTRS) · Prestige Consumer Healthcare Inc. (PBH) Viatris Inc. (VTRS) and Prestige Consumer Healthcare Inc. (PBH) run margins above the covered middle while sitting below the middle of the price range. For an owner in this position, the working question is how the earnings base is judged against base business erosion and loss of exclusivity. Below the Middle on Both Below-median multiple · below-median EBITDA margin 1 names Perrigo Company plc (PRGO) Perrigo Company plc (PRGO) sits below the middle on both price and margin, with 0% forward growth in the estimates. Mix is the live issue here: which products hold shelf and pricing, and which are exposed to erosion in the base portfolio.
- 1103 · THE AGENDA
The Question Ahead Is How to Allocate Capacity, Capital and Brand Investment
This page frames capacity, capital and brand investment as the open questions this data raises.
We frame the questions ahead as ones about where to put capacity, capital and brand investment. These are questions an owner or acquirer should work through using the cohort patterns shown earlier in this section. This is our view on where the data points, not a recommendation to act on any single name.
Everything on this page
03 · THE AGENDA The Question Ahead Is How to Allocate Capacity, Capital and Brand Investment NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 Move Mix Toward Dosage Forms Few Can Replicate Complex generics, sterile injectable and fill-finish work and biosimilars with interchangeability limit the number of credible filers and change the growth line the forward estimates pick up. Commodity oral-solid concentration pulls the other way. What changes the answer: A filing or approval in a complex dosage form where the credible filer count is low. Treat the Quality Record as a Pricing Variable Inspection outcomes, impurity findings and single-site dependency on a key earner can remove supply and value quickly. Dual-sourced critical APIs and a clean history at the plants carrying the earnings are what buyers test before they argue about adjusted EBITDA. What changes the answer: An observation, warning letter or import alert at a site behind a top earner. Defend the Brand Positions That Hold Shelf On the consumer self-care side, monograph protection, retail consumption trends and marketing support carry the earnings, and Rx-to-OTC switch optionality on an established molecule can extend a franchise well beyond an exclusivity period. What changes the answer: A change in distribution or consumption trend at a major retail customer. Decide Build Versus Buy on Capacity and Geography The record here shows consumer carve-outs from prescription parents and generics platforms changing hands, from Opella Healthcare SAS (Sanofi Consumer Health Business) to Sandoz. Adding a plant, a dosage form or regulated-market access by acquisition competes with building it internally. What changes the answer: A non-core plant or tail-brand portfolio coming out of a restructuring seller.
- 12SECTION 04
04
This divider introduces Section 04, on precedent transactions in the sector.
We move to precedent transactions next: consumer self-care assets draw the higher disclosed multiples in this record. Nine transactions in the record show where those disclosed marks land.
Everything on this page
SECTION 04 04 PRECEDENT TRANSACTIONS Consumer Self-Care Assets Draw the Higher Disclosed Multiples Nine transactions in the record, and where the disclosed marks land. 04 of 06 Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12
- 1304 · DEAL CASE STUDIES
Precedent Transactions Here Set the Benchmark on Agreed Price, Carve-Outs Included
This page tells select precedent transactions as case studies, using multiples on LTM financials at announcement where disclosed.
We tell the precedent record here as case studies, drawn from transactions with disclosed terms. Consumer self-care deals carry the higher marks, with Haleon plc recorded at 13.6x. The Opella Healthcare SAS carve-out to Clayton, Dubilier & Rice LLC was recorded at 8.8x, marking where that separation from a prescription parent was agreed. Multiples here are LTM at announcement, not directly comparable to the CY2027E basis used elsewhere in this report, so we don't draw a spread. The rest of the record sits in the appendix for a full walk-through.
Everything on this page
04 · DEAL CASE STUDIES Precedent Transactions Here Set the Benchmark on Agreed Price, Carve-Outs Included 1 of 25 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 63 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 29 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13 Nov-2025 $48.7B Kimberly-Clark Corporation Kimberly-Clark Corporation goes after a whole consumer self-care platform in Kenvue Inc. (KVUE). EV / LTM revenue 3.2x EV / LTM EBITDA 14.3x WHY THE DEAL HAPPENED Kimberly-Clark Corporation is a consumer products buyer and Kenvue Inc. (KVUE) is a consumer self-care and personal care brand portfolio, so the transaction reads as a move for shelf position, category breadth and marketing scale rather than for a prescription pipeline. At this size the buyer is taking on a whole platform, not a tail-brand bolt-on. HOW THE TARGET WAS VALUED The filing records $48.7B of enterprise value, struck at 3.2x LTM revenue.
- 14SECTION 05
05
This divider introduces Section 05, on strategic implications for owners, boards and acquirers.
We close the analysis with what this range rewards, and what sits at the bottom of it. The section ahead sets out the operating moves that change where a business stands in this set.
Everything on this page
SECTION 05 05 STRATEGIC IMPLICATIONS What This Range Rewards, and What Sits at the Bottom of It Operating moves that change where a business stands in this set. 05 of 06 Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14
- 1505 · STRATEGIC IMPLICATIONS
Faster Growth and Thinner Margins Travel Together at the Top of This Range
This page sets out strategic questions for owners, boards, acquirers and capital allocators based on the growth-margin pattern observed.
We show that faster growth and thinner margins travel together at the top of this range, and set out what that means for four audiences. For owners, mix is the lever the forward estimates read; for boards, quality and legal overhang sit inside the multiple; for acquirers, carve-outs are where the supply has been; and for capital allocation, debt service competes with the pipeline for the same cash. These are our views drawn from the analysis in this report, framed as questions rather than recommendations. So what a reader takes from this page is where to focus attention over the next twelve months.
Everything on this page
05 · STRATEGIC IMPLICATIONS Faster Growth and Thinner Margins Travel Together at the Top of This Range NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15 FOR OWNERS Mix Is the Line the Forward Estimates Read The names at the top of the range carry faster forward growth with thinner margins, so the question for management is where the next launch cohort comes from: complex dosage forms, biosimilars with channel access, or brands with switch optionality. Trimming commodity exposure changes what the estimates carry. FOR BOARDS Quality and Legal Overhang Sit Inside the Multiple Inspection outcomes, impurity findings and litigation and settlement obligations are examined before price in this sector. Protecting the earnings base — clean critical sites, dual-sourced APIs, diversification away from a single buying consortium — protects the number any multiple is applied to. FOR ACQUIRERS Carve-Outs Are Where the Supply Has Been Corporate separations of consumer self-care from prescription operations recur through this record. Buyers with a view on transitional services, supply agreements and marketing-authorisation transfer can move on assets that trade as asset deals, where timetable is set by site transfer and contract novation as much as by price.
- 16SECTION 06
06
06.
Section 06 of 06 — The Full Universe, Methodology and Sources. Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. Use this divider to reset the room before the section's pages; the progress dots show where the argument stands. 16
Everything on this page
SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16
- 1706 · PUBLIC COMPARABLES (1 OF 1)
Public Comparables on EV / EBITDA (CY2027E), Grouped by Valuation Tier
This page lists all ten companies in the universe with EV/EBITDA (CY2027E), noting which seven carry a rating and which three do not.
We list the full public comparables universe here: seven companies carry a rated EV/EBITDA figure for CY2027E, and three do not have an eligible multiple. Shading marks names above and below the sector median of 7.5x. Every rated row here also sits in the companion workbook, which carries the complete field set. So a reader checking any single name can trace it back to this page.
Everything on this page
06 · PUBLIC COMPARABLES (1 OF 1) Public Comparables on EV / EBITDA (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/EBITDA above the sector median (7.5x); amber marks below · 7 rated companies; 3 not rated (no eligible EV/EBITDA) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 7 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17 Company Ticker Segment EV EV/EBITDA (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥10.5x · median 12.3x · 2 companies Dr. Reddy's Laboratories Limited RDY Specialty and complex generics manufacturers $10.3B 14.0x 16% 22% 35 Amneal Pharmaceuticals, Inc. AMRX Specialty and complex generics manufacturers $8.9B 10.6x 9% 24% 34 CORE — 7.4x–10.5x · median 7.5x · 4 companies Teva Pharmaceutical Industries Limited TEVA Specialty and complex generics manufacturers $58.4B 10.5x 5% 26% 37 Amphastar Pharmaceuticals, Inc. AMPH Specialty and complex generics manufacturers $1.6B 7.5x 5% 29% 32 Viatris Inc. VTRS Specialty and complex generics manufacturers $34.1B 7.4x 2% 30% 32 Perrigo Company plc PRGO Specialty and complex generics manufacturers $5.5B 7.4x 1% 18% 19 DISCOUNT — <7.4x · median 6.9x · 1 companies Prestige Consumer Healthcare Inc. PBH Branded off-patent and prescription generic portfolios $3.2B 6.9x 12% 33% 46
- 1806 · PRECEDENT TRANSACTIONS (1 OF 2)
All Precedent Transactions with Disclosed Terms, Newest First
This page lists precedent transactions with disclosed terms, newest first, the first of two pages.
We list the transactions with disclosed terms here, newest first, continuing across two pages. Multiples shown are LTM at announcement where disclosed, and deal values link back to the underlying filing. The remaining transactions in this tier sit in the companion workbook. So this appendix is where a reader verifies any multiple cited earlier in the report.
Everything on this page
06 · PRECEDENT TRANSACTIONS (1 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 25 transactions with disclosed terms in this tier (54 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 63 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 29 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 25 transactions shown; the rest are in the companion workbook. Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Mar-2026 Prestige Consumer Healthcare Inc. → Breathe Right n/a n/a 11.0x Prestige Consumer Healthcare Inc. (PBH) completed the purchase of Breathe Right in March 2026 at 11.0x EV / EBITDA. It is the classic consolidator move on a single consumer self-care franchise: shelf position and marketing scale added to an existing brand platform. Nov-2025 Kimberly-Clark Corporation → Kenvue Inc. $48.7B 3.2x 14.3x Kimberly-Clark Corporation agreed to acquire Kenvue Inc. (KVUE) in November 2025 at $48.7B, recorded at 3.2x EV / Revenue and 14.3x EV / EBITDA. Announced in the record, it is the reference point on this page for a whole-company consumer self-care asset. Nov-2025 n/a → Reckitt Benckiser Group PLC n/a n/a 12.6x Reckitt Benckiser Group PLC is recorded in November 2025 at 12.6x EV / EBITDA. It sits in the same band as the other consumer self-care assets here, which is where buyer competition for branded shelf positions has been concentrated. Nov-2025 n/a → Haleon plc n/a n/a 13.6x Haleon plc is recorded in November 2025 at 13.6x EV / EBITDA. Brands with monograph protection and international distribution are being marked closer to consumer staples than to prescription generics. Nov-2025 n/a → Haleon plc n/a n/a 13.6x A second record for Haleon plc in November 2025, carrying the same EV / EBITDA marker. Repeat appearances of one target point to sustained buyer attention on large consumer self-care platforms. Oct-2024 Clayton, Dubilier & Rice LLC → Opella Healthcare SAS (Sanofi Consumer Health Business) n/a 0.7x 8.8x Clayton, Dubilier & Rice LLC completed the purchase of Opella Healthcare SAS (Sanofi Consumer Health Business) in October 2024 at 8.8x EV / EBITDA and 0.7x EV / Revenue. Separating consumer self-care from prescription operations is a recurring source of supply in this… May-2024 IAC, Inc. → Haleon plc n/a 2.2x 23.3x IAC, Inc. is recorded against Haleon plc in May 2024 at 23.3x EV / EBITDA and 2.2x EV / Revenue. The distance to the later entries on the same target is a reminder that one record is a data point rather than a band. Apr-2024 NA → PT Industri Jamu dan Farmasi Sido Muncul Tbk n/a 5.7x n/a PT Industri Jamu dan Farmasi Sido Muncul Tbk is recorded in April 2024 at 5.7x EV / Revenue. Branded consumer health outside the regulated generics channel is often marked on revenue, where the margin structure travels differently. Aug-2022 Thoma Bravo → Sandoz n/a 3.0x n/a Thoma Bravo is recorded against Sandoz in August 2022 at 3.0x EV / Revenue. A large generics platform with manufacturing footprint and geography attracts sponsor interest on a revenue basis when the portfolio mix is mid-transition.
- 1906 · PRECEDENT TRANSACTIONS (2 OF 2)
All Precedent Transactions with Disclosed Terms, Newest First
This page continues the precedent transaction list with disclosed terms, newest first, the second of two pages.
We continue the same list here, completing the transactions with disclosed terms shown newest first. The basis is unchanged: LTM multiples at announcement, linked to the underlying filing where disclosed. Any transaction not shown across these two pages sits in the companion workbook. This gives a reader the complete disclosed-terms record behind the deal commentary in Section 04.
Everything on this page
06 · PRECEDENT TRANSACTIONS (2 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 25 transactions with disclosed terms in this tier (54 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 63 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 29 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 25 transactions shown; the rest are in the companion workbook. Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Dec-2021 Vimian Group AB → GlobalOne Pet Products LLC n/a n/a 8.8x Nov-2021 Francisco Partners → Sol-Gel Technologies n/a 3.4x 10.7x Mar-2021 Anixter International Inc. → Generic Rx Pharmaceuticals business n/a 11.7x 11.7x Nov-2020 Upjohn Inc. → Mylan N.V. n/a n/a 6.5x Jan-2020 ANI Pharmaceuticals, Inc. → Amerigen Pharmaceuticals Ltd. n/a 1.4x n/a Value shown as recorded in the filing; deal value unit unresolved. Sep-2018 Aurobindo Pharma Limited → Sandoz US dermatology business and generic US oral solids portfolio n/a 0.8x n/a Value shown as recorded in the filing; deal value unit unresolved. Jul-2018 Mayne Pharma Group Limited → Spear Pharmaceuticals, Inc. (generic Efudex) n/a 1.7x n/a Value shown as recorded in the filing; deal value unit unresolved. May-2018 Lannett Company, Inc. → Endo International plc (23 generic drugs) n/a 0.1x n/a Value shown as recorded in the filing; deal value unit unresolved. Sep-2017 CVC → Teva Women’s Health n/a 2.7x n/a Value shown as recorded in the filing; deal value unit unresolved.
- 2006 · METHODOLOGY
Sources, Assumptions and Data Quality
Sources, Assumptions and Data Quality.
Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. 20
Everything on this page
06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice 20 VALUATION BASIS Primary valuation basis: EV / EBITDA on CY2027E consensus (7 of 10 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / EBITDA on CY2027E is the lead convention: it is the sector-appropriate prior for Generic and Non-Prescription Drugs and it clears the coverage gate with 7 of 10 companies (70%). EV / Revenue, P / E are carried as a cross-check. The set earns: 7 of the 7 companies with a reported forward EBITDA carry a meaningful one, so the profit multiple leads and a revenue multiple would understate what the market is pricing. DATA QUALITY & EXCLUSIONS 4 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 499 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (498) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.
- 21
The Higher Prices in This Set Sit with the Faster-Growing Names.
This closing page restates that higher prices in this set sit with the faster-growing names.
We close on the pattern that carries through this report: the higher prices in this set sit with the faster-growing names. The companion tables alongside this deck carry the full universe and source index for any figure a client wants to trace.
Everything on this page
The Higher Prices in This Set Sit with the Faster-Growing Names. NeuraCap AI — Generic and Non-Prescription Drugs Coverage September 2026 · Prepared by NeuraCap AI · Confidential Generic and Non-Prescription Drugs Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 21
Sources and methodology
This report covers Generic and Non-Prescription Drugs (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Generic and Non-Prescription Drugs) with market data and consensus estimates as of September 28, 2026. The company universe is the 10 listed companies whose core business is Generic and Non-Prescription Drugs according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Amphastar Pharmaceuticals, Inc. (AMPH), Amneal Pharmaceuticals, Inc. (AMRX), Kenvue Inc. (KVUE), Liquidia Corporation (LQDA), Prestige Consumer Healthcare Inc. (PBH), Perrigo Company plc (PRGO), Dr. Reddy's Laboratories Limited (RDY), Regencell Bioscience Holdings Limited (RGC), Teva Pharmaceutical Industries Limited (TEVA), Viatris Inc. (VTRS). The market map groups them by business vertical — Specialty and complex generics manufacturers: 7 companies (TEVA, VTRS, RDY, AMRX, PRGO, RGC, AMPH); Branded off-patent and prescription generic portfolios: 2 companies (LQDA, PBH); Consumer self-care and personal care brand portfolios: 1 company (KVUE). 7 of the 10 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.
Scope and company universe
This report covers Generic and Non-Prescription Drugs (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Generic and Non-Prescription Drugs) with market data and consensus estimates as of September 28, 2026. The company universe is the 10 listed companies whose core business is Generic and Non-Prescription Drugs according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Amphastar Pharmaceuticals, Inc. (AMPH), Amneal Pharmaceuticals, Inc. (AMRX), Kenvue Inc. (KVUE), Liquidia Corporation (LQDA), Prestige Consumer Healthcare Inc. (PBH), Perrigo Company plc (PRGO), Dr. Reddy's Laboratories Limited (RDY), Regencell Bioscience Holdings Limited (RGC), Teva Pharmaceutical Industries Limited (TEVA), Viatris Inc. (VTRS). The market map groups them by business vertical — Specialty and complex generics manufacturers: 7 companies (TEVA, VTRS, RDY, AMRX, PRGO, RGC, AMPH); Branded off-patent and prescription generic portfolios: 2 companies (LQDA, PBH); Consumer self-care and personal care brand portfolios: 1 company (KVUE). 7 of the 10 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.
What was excluded and why
4 records failed a validation gate and never feed a statistic in this report (4 excluded from aggregate). Each exclusion, with its reason: LQDA — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · LQDA — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · PRGO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · VTRS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate)
Primary valuation basis and how it was chosen
Primary valuation basis: EV / EBITDA on CY2027E consensus (7 of 10 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / EBITDA on CY2027E is the lead convention: it is the sector-appropriate prior for Generic and Non-Prescription Drugs and it clears the coverage gate with 7 of 10 companies (70%). EV / Revenue, P / E are carried as a cross-check. The set earns: 7 of the 7 companies with a reported forward EBITDA carry a meaningful one, so the profit multiple leads and a revenue multiple would understate what the market is pricing. The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 7 of 10 companies; EV / rEVenue: 9 of 10 companies; P/E: 8 of 10 companies.
How the multiples and statistics are computed
Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥10.5x, Core 7.4x–10.5x, Discount <7.4x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 7.5x = median(ev_ebitda CY2027E) (7 rated companies) · 12.3x = median(ev_ebitda CY2027E) within Premium tier (n=2) · 7.5x = median(ev_ebitda CY2027E) within Core tier (n=4) · 6.9x = median(ev_ebitda CY2027E) within Discount tier (n=1) · 9.0x = median(ev_ebitda CY2027E) | growth ≥ 5% (n=4) · 7.4x = median(ev_ebitda CY2027E) | growth < 5% (n=3) · 7.5x = median(ev_ebitda CY2027E) | EBITDA margin ≥ 26% (n=4) · 10.6x = median(ev_ebitda CY2027E) | EBITDA margin < 26% (n=3) · 33% = median Rule of 40 score (revenue growth + EBITDA margin) (n=7)
Precedent transactions: what is in the record and why
The precedent record holds the M&A transactions in Generic and Non-Prescription Drugs recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 54 transactions were recorded for this industry; 25 are shown. 29 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 29 × deal value unit unresolved; 22 × no evidence record; 6 × duplicate precedent id; 6 × divestiture roles reassigned. Case studies lead with the 1 richest stories — disclosed value, a readable multiple, newest first.
Sources
Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 503 source documents stand behind this report; by publisher domain: sec.gov, home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.
Interpretation and important notice
Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.
Sources linked in the report
- Viatris (VTRS) (sec.gov)
- Dr. Reddy's (RDY) (sec.gov)
- Amneal (AMRX) (sec.gov)
- Perrigo Company (PRGO) (sec.gov)
- Regencell (RGC) (sec.gov)
- Amphastar (AMPH) (sec.gov)
- Liquidia (LQDA) (sec.gov)
- Prestige (PBH) (sec.gov)
- Kenvue (KVUE) (sec.gov)
- $48.7B (sec.gov)
- 14.3x (sec.gov)
- n/a (sec.gov)
- 11.0x (sec.gov)
- n/a (sec.gov)
- 12.6x (sec.gov)
- 13.6x (sec.gov)
- n/a (sec.gov)
- 2.2x (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- 3.0x (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- 3.4x (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- 6.5x (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- sec.gov (498) (sec.gov)
- home.treasury.gov (1) (home.treasury.gov)
This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.
More coverage in Health Care
- M&A Update · 29 September 2026Genetic and Screening Services M&A update, 14–28 September 2026
- Sector Outlook · 29 September 2026Genetic and Screening Services Sector Outlook — September 2026
- M&A Update · 29 September 2026Health Care Data and Analytics M&A update, 14–28 September 2026
- Sector Outlook · 29 September 2026Health Care Data and Analytics Sector Outlook — September 2026
Want this analysis for a company in Generic and Non-Prescription Drugs?
Company valuation reports run the same method against a single business — public or private.
